In norepinephrine indications, which scenario best describes its use?

In norepinephrine indications, which scenario best describes its use?

• A. First-line agent for increasing heart rate
• B. Second-line vasopressor when phenylephrine is not effective
• C. Preferred agent in patients with high SVR and no tachycardia risk
• D. Used only for local vasoconstriction

Answer: (B)

Norepinephrine is a vasopressor used to restore mean arterial pressure in shock by constricting systemic vessels (alpha-adrenergic effects), which raises vascular resistance, and thus MAP. It also has some beta-1 activity, giving a bit of heart rate and contractility support to help maintain cardiac output. In the scenario described, phenylephrine is used first as a pure alpha-adrenergic vasoconstrictor. If its effect isn’t enough to achieve the target MAP, norepinephrine is added as a second-line vasopressor. This combination leverages phenylephrine’s vasoconstriction while providing norepinephrine’s additional vasoconstrictive effect plus cardiac-supporting beta-1 activity to improve perfusion pressure without relying on a single mechanism. This helps explain why norepinephrine fits best here: it’s not about increasing heart rate as the primary goal, and it’s not limited to local vasoconstriction. It’s used systemically to augment blood pressure when a first-line vasopressor (phenylephrine) is insufficient.

Norepinephrine is a vasopressor used to restore mean arterial pressure in shock by constricting systemic vessels (alpha-adrenergic effects), which raises vascular resistance, and thus MAP. It also has some beta-1 activity, giving a bit of heart rate and contractility support to help maintain cardiac output.

In the scenario described, phenylephrine is used first as a pure alpha-adrenergic vasoconstrictor. If its effect isn’t enough to achieve the target MAP, norepinephrine is added as a second-line vasopressor. This combination leverages phenylephrine’s vasoconstriction while providing norepinephrine’s additional vasoconstrictive effect plus cardiac-supporting beta-1 activity to improve perfusion pressure without relying on a single mechanism.

This helps explain why norepinephrine fits best here: it’s not about increasing heart rate as the primary goal, and it’s not limited to local vasoconstriction. It’s used systemically to augment blood pressure when a first-line vasopressor (phenylephrine) is insufficient.